What's new with glucocorticoids in severe community-acquired pneumonia?
Intensive Care Med
.
2023 Nov;49(11):1397-1399.
doi: 10.1007/s00134-023-07179-5.
Epub 2023 Aug 22.
Authors
Pierre-François Dequin
1
2
3
,
Julio A Ramirez
4
5
,
Grant Waterer
6
7
8
Affiliations
1
INSERM UMR 1100, Research Center for Respiratory Diseases, Tours University, Tours, France.
[email protected]
.
2
Médecine Intensive Réanimation and INSERM Centre d'Investigation Clinique 1415, Bretonneau University Hospital, Tours, France.
[email protected]
.
3
CRICS-TriGGERSep Network, Tours, France.
[email protected]
.
4
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, KY, USA.
5
Emeritus Professor of Medicine, Division of Infectious Diseases, University of Louisville, Louisville, KY, USA.
6
East Metropolitan Health Service, Perth, WA, Australia.
7
Royal Perth Hospital, Perth, WA, Australia.
8
University of Western Australia, Perth, WA, Australia.
PMID:
37606740
DOI:
10.1007/s00134-023-07179-5
No abstract available
MeSH terms
Community-Acquired Infections* / drug therapy
Glucocorticoids / therapeutic use
Humans
Pneumonia* / drug therapy
Substances
Glucocorticoids